Presentation is loading. Please wait.

Presentation is loading. Please wait.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer  Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Published byRagna Sunde Modified over 5 years ago

Similar presentations

Presentation on theme: "High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer  Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin."— Presentation transcript:

1 High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer 
Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin Park, MD, Sook-Whan Sung, MD, PhD, Jeong-Wook Seo, MD, PhD, Doo Hyun Chung, MD, PhD  Journal of Thoracic Oncology  Volume 5, Issue 3, Pages (March 2010) DOI: /JTO.0b013e3181ce3d1d Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 FISH images from MET FISH+ NSCLCs. A, A case with MET high polysomy showed more than 4 copies of the MET gene (orange signal) in more than 40% of tumor cells. B, An example of MET amplification revealed small (4–10 copies) or innumerable tight MET gene clusters or more than 15 copies of the MET gene in more than 10% of tumor cells. The MET to CEP7 (green signal) ratio exceeded 2. NSCLC, nonsmall cell lung cancer; FISH, fluorescence in situ hybridization. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181ce3d1d) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan-Meier curves using the log-rank test showing the overall survival of all NSCLC patients (A, B), NSCLC patients with MET FISH+ (C), NSCLC patients with stage III–IV (D), and SCC patients (E, F) according to the MET FISH+ and FISH−, or MET gene amplification status based on the UCCC criteria. NSCLC, nonsmall cell lung cancer; FISH, fluorescence in situ hybridization; SCC, squamous cell carcinoma; UCCC, the University of Colorado Cancer Center. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181ce3d1d) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier curves using the log-rank test showing the overall survival of MET FISH+ and FISH−, or gene copy number status according to EGFR FISH− NSCLCs, (A, B) and EGFR FISH+ NSCLCs (C, D). FISH, fluorescence in situ hybridization; NSCLC, nonsmall cell lung cancer; EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181ce3d1d) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer  Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin."

Similar presentations

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.
MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort  Michèle Beau-Faller, MD,

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort  Michèle Beau-Faller, MD,
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,

Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,

Similar presentations

Ads by Google